Crinetics Pharmaceuticals Inc
CRNXHealthcare|Biotechnology|USA
$83.58
-0.04 (-0.05%)
Tangible Book
$12.16
Upcoming Data Readouts (8)
Oct 2026
Est. completion
P1P2Cushing Syndrome
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
NCT05804669n=18
Dec 2026
Est. completion
P1Healthy Volunteers
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
NCT07570082n=46
May 2027
Est. completion
P3Congenital Adrenal Hyperplasia
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163n=150
Aug 2027
Est. completion
P3Carcinoid Syndrome
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054n=141
Aug 2027
Est. completion
P1P2SST2-positive Neuroendocrine Neoplasms
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252n=150
Mar 2028
Est. completion
P2Acromegaly
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
NCT04261712n=43
Jul 2029
Est. completion
P2Congenital Adrenal Hyperplasia
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823n=200
Mar 2030
Est. completion
P2P3Congenital Adrenal Hyperplasia
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841n=153
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Jan 2024
P3
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
NCT05192382Jul 2023
P3
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
NCT04837040